Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?
09:46am, Friday, 04'th Nov 2022 Zacks Investment Research
Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
07:15am, Monday, 31'st Oct 2022
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m.
Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?
04:46pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.
Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?
02:18pm, Wednesday, 26'th Oct 2022
AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.
Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?
05:34pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
On Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.
Wells Fargo, JPMorgan, Citigroup And Some Other Big Stocks Moving Higher On Friday
03:25pm, Friday, 14'th Oct 2022 Benzinga
U.S. stocks traded lower, with the Dow Jones gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.
Gravitas Education Holdings, Inc. (NASDAQ: GEHI) sh
Down 27.9% in 4 Weeks, Here's Why You Should You Buy the Dip in ADC Therapeutics SA (ADCT)
01:35pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
The heavy selling pressure might have exhausted for ADC Therapeutics SA (ADCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
Down 27.9% in 4 Weeks, Here's Why You Should You Buy the Dip in ADC Therapeutics SA (ADCT)
12:04pm, Wednesday, 12'th Oct 2022
The heavy selling pressure might have exhausted for ADC Therapeutics SA (ADCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
Down 28.5% in 4 Weeks, Here's Why ADC Therapeutics SA (ADCT) Looks Ripe for a Turnaround
01:35pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i
Down 28.5% in 4 Weeks, Here's Why ADC Therapeutics SA (ADCT) Looks Ripe for a Turnaround
11:18am, Tuesday, 11'th Oct 2022
ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
02:04pm, Wednesday, 21'st Sep 2022 Benzinga
Upgrades
For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago
Analyst Ratings for ADC Therapeutics
04:23pm, Friday, 09'th Sep 2022 Benzinga
Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
1
0
0
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
02:40pm, Friday, 09'th Sep 2022 Benzinga
Upgrades
For 3M Co (NYSE:MMM), UBS upgraded the previous rating of Sell to Neutral. For the second quarter, 3M had an EPS of $2.48, compared to year-ago quarter EPS of $2.59. The current stock perform
Expert Ratings for ADC Therapeutics
01:33pm, Friday, 09'th Sep 2022 Benzinga
ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
1
0
0
Last 3
ADC Therapeutics to Participate in Morgan Stanley's 20th Annual Global Healthcare Conference
07:15am, Tuesday, 06'th Sep 2022
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley's 20th Annual
